390 related articles for article (PubMed ID: 29290784)
1. Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.
Luo H; Ge H; Cui Y; Zhang J; Fan R; Zheng A; Zheng X; Sun Y
J Cancer; 2018; 9(1):182-188. PubMed ID: 29290784
[No Abstract] [Full Text] [Related]
2. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
3. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).
Mandaliya H; Jones M; Oldmeadow C; Nordman II
Transl Lung Cancer Res; 2019 Dec; 8(6):886-894. PubMed ID: 32010567
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
Karan C; Yaren A; Demirel BC; Dogan T; Ozdemir M; Demiray AG; Taskoylu BY; Degirmencioglu S; Dogu G; Ozhan N; Cakiroglu U; Celikyurek A
Cancer Diagn Progn; 2023; 3(6):706-715. PubMed ID: 37927800
[TBL] [Abstract][Full Text] [Related]
6. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.
Huang Q; Diao P; Li CL; Peng Q; Xie T; Tan Y; Lang JY
Medicine (Baltimore); 2020 Jan; 99(4):e18607. PubMed ID: 31977852
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Inflammatory Indexes as Prognostic Predictors of Survival in Patients Suffering From Synovial Sarcoma.
Cheng Y; Mo F; Pu L; Li Q; Ma X
Front Oncol; 2019; 9():955. PubMed ID: 31608240
[No Abstract] [Full Text] [Related]
8. Development and Assessment of Novel Predictive Nomograms Based on APRI for Hepatitis B Virus-associated Small Solitary Hepatocellular Carcinoma with Stereotactic Body Radiotherapy.
Lai L; Su T; Liang Z; Lu Y; Hou E; Lian Z; Gao H; Zhu X
J Cancer; 2020; 11(22):6642-6652. PubMed ID: 33046985
[No Abstract] [Full Text] [Related]
9. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model.
Deng Q; He B; Liu X; Yue J; Ying H; Pan Y; Sun H; Chen J; Wang F; Gao T; Zhang L; Wang S
J Transl Med; 2015 Feb; 13():66. PubMed ID: 25885254
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma.
Kwon BS; Jeong DH; Byun JM; Lee TH; Choi KU; Song YJ; Suh DS; Kim KH
J Cancer; 2018; 9(7):1127-1134. PubMed ID: 29675093
[No Abstract] [Full Text] [Related]
12. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment inflammatory indexes as prognostic predictors for survival in osteosarcoma patients.
Yang S; Wu C; Wang L; Shan D; Chen B
Int J Clin Exp Pathol; 2020; 13(3):515-524. PubMed ID: 32269690
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study.
Wang Y; Zhang H; Yang Y; Zhang T; Ma X
Front Oncol; 2019; 9():995. PubMed ID: 31649874
[No Abstract] [Full Text] [Related]
15. Prognostic significance of preoperative inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma.
Hirahara N; Matsubara T; Kawahara D; Nakada S; Ishibashi S; Tajima Y
Eur J Surg Oncol; 2017 Feb; 43(2):493-501. PubMed ID: 28034501
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy.
Chen T; Tang M; Xu X; Liang G; Xiang Z; Lu Y; Wang C; Shen W
J Clin Lab Anal; 2022 Dec; 36(12):e24772. PubMed ID: 36441595
[TBL] [Abstract][Full Text] [Related]
17. Value of markers of systemic inflammation for the prediction of postoperative progression in patients with pancreatic neuroendocrine tumors.
Yang L; Fu M; Yu L; Wang H; Chen X; Sun H
Front Endocrinol (Lausanne); 2024; 15():1293842. PubMed ID: 38370351
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic significance of preoperative lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio and neutrophil-monocyte ratio on esophageal squamous cell carcinoma patients.
Shang QX; Yang YS; Hu WP; Yuan Y; He Y; Zhao JY; Ji AF; Chen LQ
Transl Cancer Res; 2020 Jun; 9(6):3903-3914. PubMed ID: 35117757
[TBL] [Abstract][Full Text] [Related]
19. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of preoperative lymphocyte-monocyte ratio in patients with resectable esophageal squamous cell carcinoma.
Han LH; Jia YB; Song QX; Wang JB; Wang NN; Cheng YF
Asian Pac J Cancer Prev; 2015; 16(6):2245-50. PubMed ID: 25824745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
